Transgene SA (TNG.PA)
| Previous close | 1.2800 |
| Open | 1.3000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.3000 - 1.3000 |
| 52-week range | 1.0300 - 2.5500 |
| Volume | |
| Avg. volume | 37,849 |
| Market cap | 131.109M |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2200 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
Globe NewswireAvailability of Preparatory Documents for the Combined General Meeting of May 15, 2024
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available. The notice of meeting, comprising the agenda and the draft resolutions was published in the Bulletin des Annonces Légales Obligatoires (BALO) n° 42 of April 5, 2024. These notices include i
GlobeNewswireAvailability of Transgene's 2023 Universal Registration Document
TRANSGENE (Paris: TNG) today announced that its Universal registration document for the fiscal year ended December 31, 2023, was submitted to the French stock market authority (Autorité des Marchés financiers – AMF) in ESEF format and registered under the reference D.24-0274. The 2023 Universal Registration Document is available to the public under the conditions provided by applicable regulations. The document is available on the Company’s website: www.transgene.fr, in the “Investors/Financial
GlobeNewswireTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. Strasbourg, France & Tokyo, Japan, April 9, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation
